Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abacavir + lamivudine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Abacavir + lamivudine is a fixed-dose combination antiretroviral medication used for the treatment of HIV/AIDS. It contains two nucleoside reverse transcriptase inhibitors (NRTIs): abacavir and lamivudine. Both drugs work by inhibiting the action of HIV reverse transcriptase, an enzyme necessary for viral replication, thereby preventing the virus from multiplying in the body. This combination is generally recommended to be used with other antiretrovirals as part of highly active antiretroviral therapy (HAART). Abacavir + lamivudine is approved for use in adults and children weighing at least 25 kg and is taken orally as a tablet. The drug was first approved in 2004 and is included on the World Health Organization's List of Essential Medicines[1][2][4][5].
- Brand names
- KivexaEpzicom
- Other names
- abacavir/lamivudine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on abacavir + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abacavir + lamivudine.